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POTENTIAL CONCLUSIONS
The Effects of Pramipexole and Carbidopa-levodopa on 
Blocking Abnormal Activity in Gene LRRK2 Which Causes 
Loss of Dopaminergic Neurons in Parkinsons
Tiffany Yun
Department of Biological and Environmental Sciences
Sample
Collection
• Animal model: transgenic mice
• Control group and 3 different treatment groups
• Pramipexole
• Carbidopa-levodopa
• Both drugs
Data
Collection
• Unified Parkinson Disease Rating Scale 
(UPDRS)
• Dopamine transporter imaging using single-
photon emission computed tomography (SPECT) 
with 2𝛽𝛽-carboxymethoxy-3𝛽𝛽(4-idodophenyl) 
tropane (𝛽𝛽-CIT) labeled with iodine 123
• Compare clinical severity of disease and rates of 
dopamine neuron degeneration
• Parkinson's is a neurodegenerative disorder that causes damage 
to dopaminergic neurons in the brain that are essential for 
planning and controlling body movement
• More than 10 million people are living with this disease in the 
United States and there are 5,000 new cases diagnosed each 
year
• Motor symptoms and non-motor symptoms
• Pramipexole is a type of dopamine agonist that mimics 
dopamine effects. It was found to reduce the progressive loss of 
striatal dopamine neuronal function.2
• Carbidopa-levodopa has been known to wear off because 
levodopa becomes less stable.1
• One study showed that Levodopa had a lower rate of 
neurodegeneration than the placebo group.3
Figure 1. Neuroimaging of the Rate of Loss of Striatal 𝜷𝜷-CIT Uptake.2
𝛽𝛽 –CIT SPECT is a biomarker for striatal dopamine neuron terminals.
Figure 2. The Total Scores on the Unified Parkinson’s Disease Rating 
Scale (UPDRS).3
The cause of Parkinson's is unknown and there is currently no 
cure.
This study aims to identify the effects of using Pramipexole and 
Carbidopa-levodopa on blocking the activity of the mutated gene 
LRRK2 which is known to result in the loss of dopaminergic 
neurons in Parkinson's.
• Higher rate of success using Pramipexole
• Higher rate of success using Carbidopa-levodopa
• Both have the same effects of treating the symptoms of Parkinson’s
• Long term solution for treating symptoms of Parkinson’s disease
• Higher doses of Levodopa can make patients develop Dyskinesia 
(abnormal involuntary movements such as head bobbing, fidgeting, 
swaying)
• Error in neuroimaging equipment
Figure 3. The Progression of Loss of Neurons in Parkinson's. 
